This activity has been designed to meet the educational needs of primary care physicians and cardiologists.
After participating in the activity, learners should be better able to:
- APPLY knowledge of PCSK9 inhibitor mechanism of action, efficacy outcomes, safety profiles, and prescribing information into clinical practice
- EXPLAIN the possible mechanisms by which PCSK9 inhibitors could potentially mitigate morbidity and mortality outcomes associated with COVID-19
- REVIEW barriers that inhibit patient access to PCSK9 inhibitors
- SUMMARIZE strategies to improve patient access to PCSK9 inhibitors and ensure adherence and persistence to therapy